BioMarin pledges up to $588M to Merck KGaA in rare-disease land grab

BioMarin Pharmaceutical ($BMRN) bet more than half a billion dollars on the rare disease phenylketonuria Thursday. The U.S.-based biotech will pay its development partner Merck KGaA €340 million up front for worldwide rights to Kuvan (excluding Japan), plus €60 million more in sales-related milestone payments. The deal also includes €125 million in potential milestone payments on pegvaliase, an experimental PKU treatment. That's a total of €525 million, or $588 million. Release

Suggested Articles

BMS’s Opdivo has plenty of competition in its current bladder cancer indication—so it’s hoping to strike out on its own in a new area of the disease.

The Japanese approval, under the brand name Jyseleca, came a month after an FDA complete response letter that asked Gilead for more data.

The Trump Administration has opened the doors for Florida and other states to import prescription drugs from Canada—despite industry objections.